A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous.
Wójcik
C
C
Mlynarczuk
I
I
Hoser
G
G
Kawiak
J
J
Stoklosa
T
T
Gołab
J
J
Wilk
S
S
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003546:Cysteine Endopeptidases; D015853:Cysteine Proteinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D009097:Multienzyme Complexes; D046988:Proteasome Endopeptidase Complex; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D009097:Multienzyme Complexes; D014212:Tretinoin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex